Arrowhead Pharmaceuticals Inc

2026. g. 24. sept. 19:46 UTC

Arrowhead Pharmaceuticals shares fell sharply as Goldman Sachs resumed coverage with a Neutral rating and a price target of $74 amid mixed fiscal results.

2026. g. 23. sept. 23:56 UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026. g. 22. sept. 20:06 UTC

Arrowhead Pharmaceuticals Inc is higher in Tuesday's trading, having gained notably from Monday's close, despite pulling back from a mid-afternoon peak.

2026. g. 21. sept. 23:25 UTC

Arrowhead Pharmaceuticals Inc declined in after-market trading, moving lower from Monday's close and remaining near the lower end of its one-month trading range.

2026. g. 18. sept. 23:12 UTC

Arrowhead Pharmaceuticals Inc is experiencing notable strength in after-market trading, rising sharply despite initial sales figures for TRYNGOLZA being deemed unreliable by Ionis' CEO.

2026. g. 17. sept. 22:56 UTC

Arrowhead Pharmaceuticals Inc is trading roughly flat in after-market hours, maintaining little change since Thursday's close amid a notable decline over the past month.

2026. g. 16. sept. 22:31 UTC

Arrowhead Pharmaceuticals Inc is rising in after-market trading, rebounding sharply amid retail commentary on its resilience despite challenges in the biotechnology sector.

2026. g. 15. sept. 23:01 UTC

Arrowhead Pharmaceuticals is gaining in after-market hours following positive interim data from its ARO-DIMER-PA trial, amid a broader market uptrend.

2026. g. 14. sept. 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower amid broader market pressures, driven by renewed inflation concerns and supply chain disruptions.

2026. g. 11. sept. 23:26 UTC

Arrowhead Pharmaceuticals shares rose in after-market trading, amid steady U.S. inflation data and speculation about potential Federal Reserve interest rate hikes.

2026. g. 10. sept. 19:56 UTC

Arrowhead Pharmaceuticals shares are higher during Thursday's session, despite fluctuations and remaining below the 20-day moving average amid broader market trends.

2026. g. 9. sept. 19:36 UTC

Arrowhead Pharmaceuticals is lower today despite Citi initiating coverage with a "Buy" rating and a price target of $108. The stock has declined for four sessions.

2026. g. 8. sept. 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading lower today, following Citi's initiation of coverage with a Buy rating and a $108 price target.

2026. g. 4. sept. 23:10 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours following Friday's close. Broader market caution amid mixed economic signals may be influencing this movement.

2026. g. 3. sept. 19:46 UTC

Arrowhead Pharmaceuticals shares are higher as the company announces participation in several upcoming investor conferences, enhancing visibility among investors and analysts.

2026. g. 2. sept. 23:01 UTC

Arrowhead Pharmaceuticals Inc is trading lower in after-market hours, reflecting a notable decline since Wednesday's close amid broader market tensions and rising oil prices.

2026. g. 1. sept. 19:46 UTC

HC Wainwright reiterated its Buy rating on Arrowhead Pharmaceuticals, maintaining a $120 price target as shares advance during the session.

2026. g. 31. aug. 20:01 UTC

Arrowhead Pharmaceuticals shares are lower despite promising Phase 3 results for plozasiran, which showed significant triglyceride reductions in patients.

2026. g. 28. aug. 21:01 UTC

Arrowhead Pharmaceuticals Inc. shares are higher in after-market trading, continuing a modest rise since Friday's close, despite remaining below the 20-day moving average.

2026. g. 26. aug. 19:56 UTC

Arrowhead Pharmaceuticals shares are lower today, trading within a narrow range without any specific news or developments identified.

2026. g. 25. aug. 23:31 UTC

Arrowhead Pharmaceuticals shares moved higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

2026. g. 21. aug. 19:46 UTC

Arrowhead Pharmaceuticals shares are lower as Director Michael Perry sold 11,600 shares, reducing his ownership. Rising Treasury yields may also affect sentiment in biotechnology.

2026. g. 20. aug. 21:26 UTC

Arrowhead Pharmaceuticals Inc shares are lower during after-market hours. Broader market pressure from rising U.S. Treasury yields may be influencing sentiment.

2026. g. 19. aug. 19:26 UTC

Arrowhead Pharmaceuticals shares are higher Wednesday, supported by gains in the biotech sector, as the stock remains above its 20-day moving average.

2026. g. 18. aug. 23:01 UTC

Arrowhead Pharmaceuticals shares are lower in after-market hours, continuing a decline since Tuesday's close amid broader market concerns over rising U.S. Treasury yields.

2026. g. 14. aug. 19:26 UTC

Arrowhead Pharmaceuticals Inc shares are higher during Friday's session, trading above their 20-day moving average and near the top of their one-month range.

2026. g. 13. aug. 20:06 UTC

Arrowhead Pharmaceuticals Inc is declining today amid broader sector pressures, reflecting challenges in the biotech sector linked to the performance of LABU.

2026. g. 12. aug. 21:01 UTC

Arrowhead Pharmaceuticals shares are higher in after-market hours, buoyed by positive market sentiment following comments on interest rates from Economic Advisor Phelan.

2026. g. 11. aug. 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher today, remaining above its 20-day moving average amid geopolitical tensions and anticipation of U.S. inflation reports.

2026. g. 6. aug. 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower during Thursday's session, despite earlier rebounding from a session high. No specific news was identified to explain the decline.